<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03542916</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_EPO_101</org_study_id>
    <nct_id>NCT03542916</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics Study of CJ-40001 and NESP® After Single Dose Administration in Health Male Volunteers</brief_title>
  <official_title>A Single-blind, Randomized, Single-dose, Crossover Study to Compare the Pharmacokinetics and Safety Following Administration of CJ-40001 and NESP® in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HK inno.N Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HK inno.N Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the pharmacokinetics and safety after a single
      subcutaneous or intravenous administration of CJ-40001 and NESP® in healthy male volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare the pharmacokinetics and safety after a single
      subcutaneous or intravenous administration of CJ-40001 and NESP in healthy male volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess Cmax of darbepoetin alfa in SC treatment group</measure>
    <time_frame>SC treatment:Pre-dose and after dose up to 16 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess Cmax of darbepoetin alfa in IV treatment group</measure>
    <time_frame>IV treatment:Pre-dose and after dose 12 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess AUClast of darbepoetin alfa in SC treatment group</measure>
    <time_frame>SC treatment:Pre-dose and after dose up to 16 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess AUClast of darbepoetin alfa in IV treatment group</measure>
    <time_frame>IV treatment:Pre-dose and after dose 12 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess Temax of reticulocyte, hemoglobin, hematocrit, RBC in SC treatment group</measure>
    <time_frame>SC treatment:Pre-dose and after dose up to 16 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess Emax of reticulocyte, hemoglobin, hematocrit, RBC in SC treatment group</measure>
    <time_frame>SC treatment:Pre-dose and after dose up to 16 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess AUEClast of reticulocyte, hemoglobin, hematocrit, RBC in SC treatment group</measure>
    <time_frame>SC treatment:Pre-dose and after dose up to 16 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess Temax of reticulocyte, hemoglobin, hematocrit, RBC in IV treatment group</measure>
    <time_frame>IV treatment:Pre-dose and after dose 12 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess Emax of reticulocyte, hemoglobin, hematocrit, RBC in IV treatment group</measure>
    <time_frame>IV treatment:Pre-dose and after dose 12 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess AUEClast of reticulocyte, hemoglobin, hematocrit, RBC in IV treatment group</measure>
    <time_frame>IV treatment:Pre-dose and after dose 12 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>CJ-40001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CJ-40001 60ug SC, IV injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NESP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NESP 60ug SC, IV injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CJ-40001 60ug</intervention_name>
    <description>CJ-40001 60ug SC, IV injection</description>
    <arm_group_label>CJ-40001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NESP 60ug</intervention_name>
    <description>NESP 60ug SC, IV injection</description>
    <arm_group_label>NESP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male aged 19 to 55 years at the screening

          -  Subject with BMI between 19 kg/m2 and 28 kg/m2 (inclusive)

          -  Subject who is able to participate in the whole study process

          -  Subject who provided written informed consent voluntarily after being fully informed
             of the study objectives, procedures and the investigational product

        Exclusion Criteria:

          -  Subject who has a medical history of gastrointestinal, cardiovascular, respiratory,
             hepatobiliary, hematologic/oncologic, neuropsychologic, endocrinological, immunologic
             or renal disease that may be aggravated by the investigational product

          -  Subject with a systolic blood pressure of equal to or greater than 140 or less than 90
             mmHg or with a diastolic blood pressure of equal to or greater than 90 or less than 60
             mmHg

          -  Subject who has allergic disease that needs to be treated

          -  Subject with a history of drug allergies to any ingredient of the investigational
             product or marketed drug

          -  Subject with a blood hemoglobin value less than 13 g/dL or more than 17 g/dL

          -  Subject with a blood reticulocyte value more than the upper reference limit

          -  Subject with a blood vitamin B12 or ferritin or transferrin value less than the lower
             reference limit

          -  Subject with any non-negative results in blood serology (HBV, HCV, HIV, RPR) tests and
             in an examination of syphilis

          -  Subject who smokes more than 10 cigarettes per day

          -  Subject who consumes alcohol more than 140 g per week

          -  Subject with a history of drug abuse

          -  Subject who was administered with any investigational product, erythropoietin or iron
             supplement within 60 days prior to the screening

          -  Subject who donated whole blood within 60 days or blood components within 30 days
             prior to the screening

          -  Subject who took any herbal medicine within 30 days or any prescription drug within 14
             days or over-the-counter drug considered to affect study within 10 days prior to the
             screening

          -  Subject who does not agree to use medically acceptable methods of contraception or who
             has plan to provide sperm during the study period

          -  Subject whom the investigator determined to have clinically significant findings in
             ECG

          -  Subject whose liver function is decreased with an AST, ALT or bilirubin value more
             than 1.5 times the upper reference limit

          -  Subject whose renal function is decreased with a GFR value calculated using MDRD
             equation less than the lower reference limit

          -  Subject whom the investigator determined to have clinically significant findings in
             clinical laboratory test

          -  Subject who is inappropriate as a subject of this study by the investigator's decision
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>January 26, 2015</study_first_submitted>
  <study_first_submitted_qc>May 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2018</study_first_posted>
  <last_update_submitted>May 30, 2018</last_update_submitted>
  <last_update_submitted_qc>May 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

